EQUILLIUM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | 0.00% |
|
-9.41% | +113.00% |
Presenter SpeechThomas Smith (Analysts)All right. Good morning, everyone, and thanks for joini...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Companyâs pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Companyâs EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.54
USD
Average target price
6.75
USD
Spread / Average Target
+338.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +113.00% | 54.29M | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Transcript : Equillium, Inc. Presents at SVB Leerink 10th Annual Global Healthcare Conference 2021, Feb-25-2021 11